Cholangiocarcinoma

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Cholangiocarcinoma is an adenocarcinoma arising from the biliary epithelium. Anatomical classification is clinically decisive: intrahepatic CCA forms within liver parenchyma; perihilar CCA involves the hepatic duct confluence; distal CCA lies below the cystic-duct insertion towards the ampulla. Perihilar and distal lesions obstruct bile flow early, whereas an intrahepatic lesion can become large before jaundice. Mimics include benign postoperative or inflammatory strictures, IgG4-related disease, stones and primary sclerosing cholangitis itself.

The BSG pathway emphasises high-quality imaging and specialist coordination. Multiphasic CT stages the primary, vascular relationships, nodes, lungs and peritoneum. MRI/MRCP better delineates proximal biliary spread and intrahepatic satellite disease. PET-CT may contribute to nodal and distant staging in the specialist pathway. Tumour markers provide context but not proof. Cytology and histology can be insensitive, so a negative brush result does not automatically make a radiologically malignant stricture benign.

Management is technically interdependent. A drainage choice can determine which future liver remnant remains usable; a needle tract can affect a transplant or resection pathway; a prolonged ERCP can cause pancreatitis and delay surgery. The HPB MDT therefore coordinates radiology, endoscopy, interventional radiology, surgery, pathology and oncology before invasive steps whenever clinical stability permits. Resectable disease goes to a high-volume centre. Unresectable disease may receive biliary palliation, systemic treatment, biomarker-directed therapy, radiotherapy in selected settings and early holistic palliative care.

Key points

Classify cholangiocarcinoma as intrahepatic, perihilar or distal because symptoms, imaging, tissue route, drainage, surgery and molecular patterns differ materially by site.
Extrahepatic disease commonly presents with progressive jaundice, dark urine, pale stool and pruritus; intrahepatic tumours may present as a liver mass, pain, weight loss or incidental imaging abnormality.
Primary sclerosing cholangitis, choledochal cysts and selected chronic biliary inflammatory disorders increase risk, but most patients do not have an obvious pre-existing syndrome.
BSG recommends multiphasic contrast CT of chest, abdomen and pelvis for all types; add contrast MRI and MRCP for perihilar and intrahepatic tumours to define biliary extent and satellites.
Obtain staging imaging before endoscopic intervention when the patient is stable, because stents and inflammation can obscure anatomy; cholangitis or organ-threatening obstruction may require immediate drainage instead.
CA19-9 cannot diagnose cholangiocarcinoma: cholestasis and infection can elevate it, and people lacking Lewis antigen may not produce it despite cancer.
Tissue strategy is site- and intent-dependent; BSG requires MDT planning, and perihilar endotherapy should not proceed before discussion at an HPB treatment centre.
R0 surgical resection is the only established curative treatment; advanced disease should receive early molecular profiling, specialist systemic-therapy review and palliative support alongside active oncology.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Chronic biliary inflammation

Primary sclerosing cholangitis and selected longstanding inflammatory cholangiopathies increase malignant transformation risk through repeated epithelial injury and repair.

Congenital biliary abnormalities

Choledochal cysts and other duct malformations promote bile stasis and chronic inflammation, increasing lifetime cholangiocarcinoma risk.

Sporadic disease

Most patients have no recognised pre-existing syndrome; age and acquired molecular changes contribute across intrahepatic, perihilar and distal tumours.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Dysplastic transformation
Chronic injury and accumulated genetic alterations drive cholangiocytes from metaplasia or dysplasia towards invasive adenocarcinoma over time.
2
Infiltrative tumour growth
Cancer spreads along bile ducts, through liver parenchyma or around hilar vessels, with anatomical site determining resectability and drainage strategy.
3
Obstruction and dissemination
Extrahepatic growth blocks bile flow, while lymphatic, vascular and peritoneal spread causes nodal disease, metastases and progressive systemic decline.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Extrahepatic obstruction

Progressive painless jaundice, pruritus, pale stool, dark urine and weight loss suggest a perihilar or distal malignant stricture, although stones remain a common mimic.

Intrahepatic mass presentation

Right-upper-quadrant discomfort, anorexia, weight loss or an incidental liver lesion without jaundice can represent intrahepatic cholangiocarcinoma and needs dedicated staging.

PSC-associated change

New dominant or relevant stricture, worsening cholestasis, bacterial cholangitis, weight loss or constitutional decline in primary sclerosing cholangitis demands expedited specialist assessment.

Acute infected obstructionRed flag

Fever, rigors, hypotension or confusion with malignant jaundice indicates cholangitis and requires emergency sepsis treatment plus appropriately planned biliary decompression.

Stent dysfunctionRed flag

Recurrent jaundice, pale stool, fever or pain after palliation suggests occlusion or migration; BSG advises cross-sectional reassessment before repeat endotherapy.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Multiphasic contrast CT chest, abdomen and pelvisFirst step
Why
Stage every suspected CCA, define primary extent and vascular relations, and identify nodal or distant spread.
Interpretation and limitations
Resectability depends on site, vascular and biliary involvement, future liver remnant and metastases; the regional HPB MDT interprets these together.
02
Contrast MRI with MRCP
Why
Map intrahepatic and perihilar tumour, ductal longitudinal extent, satellite lesions and the liver planned to remain after surgery.
Interpretation and limitations
Complex hilar strictures require sectoral analysis; baseline imaging is most informative before contrast injection, stenting or procedure-related inflammation.
03
Liver profile, FBC, renal profile and coagulation
Why
Quantify cholestasis, infection, anaemia and organ function relevant to contrast, drainage, operation and systemic treatment.
Interpretation and limitations
Bilirubin and INR reflect obstruction and nutrition as well as hepatic reserve; correct reversible problems without obscuring the need for source control.
04
CA19-9 with clinical context
Why
Provide a non-specific baseline that may support longitudinal specialist assessment after cholangitis and obstruction are addressed.
Interpretation and limitations
An elevated value is not diagnostic, and a low value cannot exclude disease; interpret only alongside imaging, pathology and Lewis-antigen biology.
05
MDT-planned cytology or histology
Why
Secure diagnosis and sufficient material for immunohistochemistry and molecular profiling without compromising curative options.
Interpretation and limitations
Brushings can be falsely negative. Intrahepatic mass or metastasis biopsy, EUS sampling and ERCP sampling have different uses and seeding implications.
06
Molecular profiling
Why
Identify actionable alterations and inform later-line or trial options in confirmed disease, particularly intrahepatic CCA.
Interpretation and limitations
BSG recommends early profiling, but tissue adequacy and current NHS access determine which findings translate into treatment.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Choledocholithiasis

Fluctuating pain or jaundice with a demonstrable duct stone favours benign obstruction, although a stone does not exclude an underlying malignant stricture.

Benign inflammatory stricture

PSC, postoperative narrowing and IgG4-related cholangitis can mimic cancer; multidisciplinary imaging, tissue strategy and disease context prevent premature labelling.

Pancreatic or hepatic tumour

A pancreatic-head mass causes distal obstruction, while hepatocellular carcinoma or metastasis has different enhancement, background-liver and histological features.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01DiagnosisProtected staging sequenceFirst stepImaging, jaundice or a dominant stricture raises a credible suspicion of cholangiocarcinoma without emergency sepsis.

1Classify the likely site, review benign alternatives and send liver, renal, clotting and inflammatory blood tests with a careful biliary history.
2Obtain multiphasic CT of chest, abdomen and pelvis, adding contrast MRI and MRCP for proximal or intrahepatic anatomy before endoscopy.
3Route the complete dataset rapidly to the regional HPB MDT, which defines resectability, drainage objectives and the safest tissue route.
4DefinitiveExplain uncertainty honestly: negative cytology may not exclude cancer, and surgery can occasionally provide both cure and definitive diagnosis.

02JaundicePurposeful biliary drainageObstruction causes cholangitis, severe symptoms, organ consequences or a specialist pre-treatment indication.

1Treat active cholangitis immediately and involve experienced endoscopy, radiology, surgery and anaesthesia according to physiological severity.
2For a stable potentially operable distal lesion, follow local HPB advice because rapid surgery may avoid the complications of routine preoperative ERCP.
3For perihilar disease, do not undertake endotherapy until the HPB centre has selected the future liver remnant and intended drainage sectors.
4Document stent type, drained segments, exchange plan and rapid-access route for recurrent pain, jaundice or fever.

03TreatmentResectable or advanced diseaseSpecialist staging and pathology review have established the likely extent and treatment intent.

1Refer potentially resectable disease to a high-volume specialist centre for operation, liver-remnant optimisation and selective staging laparoscopy as required.
2After resection, discuss current adjuvant therapy and surveillance through the biliary cancer MDT rather than copying an historical regimen.
3For advanced disease, combine molecular profiling with nationally commissioned systemic-treatment, radiotherapy or clinical-trial assessment according to performance status.
4Offer a cancer nurse specialist, dietetic input and early palliative assessment while continuing appropriate oncology; supportive care is not treatment abandonment.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

BSG recommends considering a twenty-four-week adjuvant course after resection, subject to contemporary oncology assessment and patient choice.

Capecitabine after resection

Use only the current specialist adjuvant protocol, typically delivered over a defined course with body-surface-area calculation and cycle review.

Check DPD status under current policy, renal and liver function, diarrhoea, mucositis, hand-foot toxicity, cardiac risk and interacting anticoagulants.

Treats unresectable or metastatic disease in people with adequate performance and organ function after specialist discussion.

First-line advanced biliary cancer regimen

Deliver a nationally commissioned oncology protocol such as gemcitabine-platinum with any approved immunotherapy component, using current cycle-specific prescribing.

Approvals evolve; monitor marrow, renal, hepatic, hearing, infection and immune-mediated toxicity and adapt to biliary sepsis or declining performance.

May relieve cholestatic itch while drainage and tumour-directed plans are pursued.

Cholestyramine for pruritus

Use current BNF oral dosing in selected patients and separate administration from other oral medicines because binding reduces absorption.

It does not open an obstructed duct, can cause constipation and may worsen medicine or fat-soluble vitamin absorption; seek hepatology advice for refractory itch.

Treats infection complicating malignant obstruction as a bridge to urgent source control.

Antimicrobials for cholangitis

Start the local intravenous biliary-sepsis regimen promptly at BNF-adjusted doses and revise after blood or bile cultures and drainage.

Prior stents and hospital exposure alter resistant-organism risk; antibiotics neither stage cancer nor guarantee duct patency after treatment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Cholangitis and sepsis

Incomplete drainage of obstructed ducts permits ascending infection, especially after instrumentation, causing recurrent bacteraemia and organ failure.

Cholestatic liver failure

Persistent obstruction causes pruritus, malabsorption, coagulopathy and progressive hepatic dysfunction, while repeated procedures may add infectious risk.

Local invasion and metastasis

Vascular encasement, hepatic infiltration and distant spread can remove curative options and cause pain, cachexia and declining performance status.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

After drainage, follow temperature, bilirubin, alkaline phosphatase, renal function and symptoms while checking every intended liver sector is adequately decompressed.
Maintain a stent recall system and obtain cross-sectional imaging for recurrent pain or suspected dysfunction before repeated endotherapy when feasible.
During systemic treatment, oncology monitors blood count, renal and hepatic function, infection, performance status and regimen-specific toxicities each cycle.
After curative-intent resection, use the regional surveillance protocol and investigate new weight loss, pain, cholestasis or constitutional change promptly.
Review nutrition, sarcopenia, mood, carer burden, symptom control and advance-care preferences alongside tumour response at every major transition.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Site changes everything

The labels intrahepatic, perihilar and distal predict different imaging priorities, operations, drainage techniques and molecular opportunities.

Images precede instruments

Baseline cross-sectional staging before ERCP preserves duct and vascular information unless emergency infection makes drainage more urgent.

Negative brushing is weak

Biliary cytology has imperfect sensitivity, so benign wording cannot cancel a highly suspicious multidisciplinary radiological picture.

Hilar drainage is strategic

The duct drained should align with the planned future liver remnant; more contrast and more stents are not automatically better.

Profiling needs tissue

Plan biopsy handling early enough to preserve material for immunohistochemistry and genomic testing after diagnostic sections.

11Common pitfallsFrequent interpretation and management errors.

01
Calling every malignant biliary stricture a single disease without anatomical classification.
02
Requesting ERCP before staging CT and MRI in a clinically stable perihilar presentation.
03
Using CA19-9 alone to diagnose or exclude cholangiocarcinoma.
04
Sampling a potentially curable lesion through an unplanned route before MDT review.
05
Draining multiple hilar sectors without a future-liver-remnant strategy.
06
Postponing palliative and nutritional care until anticancer options are exhausted.